Barrick Mining Corporation ("Barrick" or the "Company") today reported a solid start to the financial year, making significant headway on its long-term strategy and advancing its global portfolio of ...

Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update at 2025 ASCO® Annual Meeting - Based on the Company's current operating ...

First Quarter 2025 Financial Results Collaboration revenue for the three months ended March 31, 2025 increased by $18.6 million as compared to the three months ended March 31, 2024, primarily as a ...

Click the FOLLOW button to be the first to know about this artist's upcoming lots, sold lots, exhibitions and articles ...